^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients

Excerpt:
...MET gene amplifications 5....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment

Excerpt:
...- Although it is preferred to enroll patients with solid tumors harboring MET amplification, this will...
Trial ID:
More C2 evidence
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment

Excerpt:
...Patients with MET amplification....
Trial ID:
Less C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Efficacy, and Biomarkers

Published date:
04/21/2022
Excerpt:
Notably, in gastric cancer, response was only observed in patients with MET amplification (copy number 9.7-18.4), with an objective response rate of 35.7% and a disease control rate of 64.3%...The RP2D of savolitinib was established as 600 mg QD or 500 mg BID in Chinese patients. The promising response observed in patients with gastric cancer with c-met amplification...
DOI:
10.1093/oncolo/oyab066
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Matched therapies for advanced gastric cancer based on genotype: A real-world study in China.

Published date:
05/19/2021
Excerpt:
...11 (37%) harbored c-MET amplification/overexpression (received savolitinib or crizotinib, cohort A)....three of 11 patients had an objective response (1 complete response and 2 partial responses, objective response rate (ORR) 27%), disease control rate (DCR) was 45%, median progression-free survival (mPFS) was 2.1 months, and median overall survival (mOS) was 3.7 months.
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial

Published date:
07/17/2019
Excerpt:
Circulating tumor (ctDNA) analysis demonstrated good correlation between high MET copy number by ctDNA and response to savolitinib.
DOI:
10.1158/2159-8290.CD-19-0442